Satiety inducing composition

Details Satiety inducing composition Satiety inducing composition

2003-06-13

2009-11-17

Russel, Jeffrey E (Department: 1654)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Food or edible as carrier for pharmaceutical

C426S583000, C426S648000, C514S021800, C530S343000

Reexamination Certificate

active

07618648

ABSTRACT:
The invention provides the use of a whey protein and/or whey protein hydrolysate which stimulate the cellular release of the satiety peptides choleocystokinin and glucagon-like-peptide in the preparation of edible compositions. The edible compositions can be used to control body weight and have beneficial effects on satiety. Edible compositions are also provided.

REFERENCES:
patent: 5039532 (1991-08-01), Jost et al.
patent: 5254351 (1993-10-01), De Boer et al.
patent: 5821217 (1998-10-01), Forse et al.
patent: 6207638 (2001-03-01), Portman
patent: 6630320 (2003-10-01), Davis et al.
patent: 2002/0019334 (2002-02-01), Portman
patent: 2002/0037830 (2002-03-01), Berthelsen et al.
patent: 2002/0044988 (2002-04-01), Fuchs et al.
patent: 2002/0061359 (2002-05-01), Baker et al.
patent: 2002/0081315 (2002-06-01), Katz et al.
patent: 2003/0004095 (2003-01-01), Reimer et al.
patent: 2003/0165574 (2003-09-01), Ward et al.
patent: 2004/0248768 (2004-12-01), Garcia-Rodenas et al.
patent: 2005/0238694 (2005-10-01), Gerhardt et al.
patent: 2006/0105938 (2006-05-01), Siemensma et al.
patent: 2006/0159770 (2006-07-01), Garcia-Rodenas et al.
patent: 2006/0171992 (2006-08-01), Gerhardt et al.
patent: 2 489 942 (2004-01-01), None
patent: 629 350 (1994-12-01), None
patent: 1 034 704 (2000-09-01), None
patent: 1 112 693 (2001-07-01), None
patent: 1 201 137 (2002-05-01), None
patent: WO 93/04593 (1993-03-01), None
patent: 98/02165 (1998-01-01), None
patent: 99/49741 (1999-10-01), None
patent: 01/37850 (2001-05-01), None
patent: WO 01/37850 (2001-05-01), None
patent: 01/43563 (2001-06-01), None
patent: 01/85984 (2001-11-01), None
patent: 02/15719 (2002-02-01), None
patent: 2004/002241 (2004-01-01), None
patent: WO 2004/024177 (2004-03-01), None
patent: WO 2004/049833 (2004-06-01), None
patent: WO 2004/049834 (2004-06-01), None
patent: WO 2004/056207 (2004-07-01), None
patent: WO 2004/069265 (2004-08-01), None
patent: WO 2005/000325 (2005-01-01), None
patent: WO 2007/116091 (2007-10-01), None
http://www.wheyprotein.com/sec6.html.
Aoyama et al. Effect of Soy and Milk Whey Protein Isolates . . . Bioscience Biotechnology and Biochemistry. 2000, vol. 64, No. 12, pp. 2594-2600.
Hall et al. Investigation into the effects of casein and whey protein . . . Proceedings of the Nutrition Society. 2001, vol. 60, p. 227A.
Kelly et al. Innovative Dairy Ingredients. The World of Food Ingredients. Oct./Nov. 2002, pp. 24-26, 28, 30, and 32.
Biozate 1. Nutraceuticals World. Nov, 2002 (printed Mar. 24, 2009).
Pins et al. The Antihypertensive Effects Of A Hydrolyzed Whey Protein Supplement. Cardiovascular Drugs and Therapy. May 2002, vol. 16, Supplement 1, p. 68, Abstract P370.
PCT International Search Report on International Application No. PCT/EP 03/06212 dated Nov. 4, 2003.
Stolk et al., “Gallbladder Motility and Cholecystokinin Release during Long-Term Enteral Nutrition in Patients with Crohn's Disease”, Scan J Gastroenterol, 1994, 29: 934-939.
Nishi et al., “Dietary Protein Peptic Hydrolysates Stimulate Cholecystokinin Release Via Direct Sensing by Rat Intestinal Mucosal Cells”, 2001, Exp. Biol. Med, 226:1031-1036.
Deming et al., “Effect of a Hypocaloric Diet, Increased Protein Intake and Resistance Training on Lean Mass Gains and Fat Mass Loss in Overweight Police Officers”, 2000, Ann. Nutr. Metab., 44:21-29.
Communication of a Notice of Opposition dated Nov. 23, 2007, Application No. 03761459.1-1221/1517619.
Drucker, “Development of Glucagon-Like Peptide-1-Based Pharmaceuticals as Therapeutic Agents for the Treatment of Diabetes”, Current Pharmaceutical Design, 2001, 7, pp. 1399-1412.
Zander et al., “Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study”, the Lancet, vol. 359, Mar. 9, 2002, pp. 824-830.
Toft-Nielsen, “Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes” J. Clinical Endocrinol Metab 2001, 8/86(8): 3853-60.
Sensi et al., “Chronobiological Aspects of Weight Loss in Obesity: Effects of Different Meal Timing Regimens”, Chronobiology International, vol. 4, No. 2, 1987, pp. 251-261.
Harper, “Biological Properties of Whey Components A Review”, The American Dairy Products Institute, 2001, pp. 1-20.
Harper, “Biological Properties of Whey Components A Review”, The American Dairy Products Institute, 2004, pp. 1-44.
Nuttal et al., “Effect of Protein Ingestion on the Glucose and Insulin Response to a Standarized Oral Glucose Load”, Diabetes Care, vol. 7, No. 5, Sep.-Oct. 1984, pp. 465-470.
Abubakar et al. “Structural Analysis of New Antihypertensive Peptides Derived from Cheese Whey Protein by Proteinase K Digestion”, J. Dairy Science, vol. 81, No. 12, 1998, pp. 3131-3138.
Co-pending Application: Applicant: Gerhardt et al., U.S. Appl. No. 10/539,434, filed Jan. 13, 2006.
Information taken from the Mintel Global New Products Database Record #10089034 (www.gnpd.com) for Designer Whey Protein Blast Supplement Drink, “date published” Jul. 24, 2001.
Information taken from the Mintel Global New Products Database Record #10089034 (www.gnpd.com) for Mintel, Designer Whey Protein Blast Supplement Drink, “date published” Feb. 22, 2002.
Information taken from Internet (www.designerwhey.com) on May 2008 regarding Designer Whey citing the History of Whey.
Information taken from the Internet (www.designerwhey.com) May 2008 on Designer Whey Protein and various products.
Press release from Davisco Foods International re award for its Patented Hypertension-Reducing Whey Protein, taken from the Internet on May 2008 (www.designerwhey.com) dated May 28, 1999.
Press Release, “Antihypertensive Effects of Whey Protein Hydrolysates in Rats Reduces Mean Arterial Blood Pressure,” dated Jun. 12, 2000 taken from Davisco Foods International website on May 2008.
Information from the Internet on Designer Whey, Science at Work, Davisco Foods International, accessed May 9, 2008.
Information taken from the Internet (www.designerwhey.com) on Research & Innovation of whey protein, Davisco Foods International, accessed May 9, 2008.
Patent Abstracts of Japan Publication No. 2004051623 A, Feb. 19, 2004.
“Whey Protein Hydrolysate”, Nutraceuticals NOW, Summer 2001.
Houston, “The Role of Vascular Biology, Nutrition, and Nutraceuticals in the Prevention and Treatment of Hypertension”, Journal of the American Nutraceutical Association, Supplement No. 1, Apr. 2002, pp. 1-71.
Langley-Danysz, “Les peptides bio-actifs du lait deviennent une réalité”, Techno Solutions, May 2002, p. 66-67 (with English abstract).

Affiliated with

Also associated with

Rating

Satiety inducing composition does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Satiety inducing composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Satiety inducing composition will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4080693